282 related articles for article (PubMed ID: 29756298)
1. Primary whole-gland ablation for localized prostate cancer with high-intensity focused ultrasound: The important predictors of biochemical recurrence.
Chen PY; Chiang PH; Liu YY; Chuang YC; Cheng YT
Int J Urol; 2018 Jun; 25(6):615-620. PubMed ID: 29756298
[TBL] [Abstract][Full Text] [Related]
2. Predictors of prostate-specific antigen biochemical recurrence in patients undergoing primary whole-gland prostate cryoablation.
Liu YY; Chiang PH; Chuang YC; Lee WC; Cheng YT; Wang HJ
Ann Surg Oncol; 2015 May; 22(5):1612-7. PubMed ID: 25287436
[TBL] [Abstract][Full Text] [Related]
3. Predictors of biochemical recurrence after Retzius-sparing robot-assisted radical prostatectomy: Analysis of 359 cases with a median follow-up period of 26 months.
Abdel Raheem A; Chang KD; Alenzi MJ; Ham WS; Han WK; Choi YD; Rha KH
Int J Urol; 2018 Dec; 25(12):1006-1014. PubMed ID: 30276864
[TBL] [Abstract][Full Text] [Related]
4. High-intensity Focused Ultrasound (HIFU) as salvage therapy for radio-recurrent prostate cancer: predictors of disease response.
Dason S; Wong NC; Allard CB; Hoogenes J; Orovan W; Shayegan B
Int Braz J Urol; 2018; 44(2):248-257. PubMed ID: 29211405
[TBL] [Abstract][Full Text] [Related]
5. Evolution and outcomes of 3 MHz high intensity focused ultrasound therapy for localized prostate cancer during 15 years.
Thüroff S; Chaussy C
J Urol; 2013 Aug; 190(2):702-10. PubMed ID: 23415962
[TBL] [Abstract][Full Text] [Related]
6. Five-Year Biochemical Progression-Free Survival Following Salvage Whole-Gland Prostate Cryoablation: Defining Success with Nadir Prostate-Specific Antigen.
Kovac E; ElShafei A; Tay KJ; Mendez M; Polascik TJ; Jones JS
J Endourol; 2016 Jun; 30(6):624-31. PubMed ID: 26915721
[TBL] [Abstract][Full Text] [Related]
7. Whole-gland ablation of localized prostate cancer with high-intensity focused ultrasound: oncologic outcomes and morbidity in 1002 patients.
Crouzet S; Chapelon JY; Rouvière O; Mege-Lechevallier F; Colombel M; Tonoli-Catez H; Martin X; Gelet A
Eur Urol; 2014 May; 65(5):907-14. PubMed ID: 23669165
[TBL] [Abstract][Full Text] [Related]
8. Relationship between prostate volume, prostate-specific antigen nadir, and biochemical control.
Kaminski JM; Hanlon AL; Horwitz EM; Pinover WH; Mitra RK; Hanks GE
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(4):888-92. PubMed ID: 11958880
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen screening impacts on biochemical recurrence in patients with clinically localized prostate cancer.
Hashimoto T; Ohori M; Shimodaira K; Kaburaki N; Hirasawa Y; Satake N; Gondo T; Nakagami Y; Namiki K; Ohno Y
Int J Urol; 2018 Jun; 25(6):561-567. PubMed ID: 29633374
[TBL] [Abstract][Full Text] [Related]
10. Prostate Specific Antigen Criteria to Diagnose Failure of Cancer Control following Focal Therapy of Nonmetastatic Prostate Cancer Using High Intensity Focused Ultrasound.
Huber PM; Afzal N; Arya M; Boxler S; Dudderidge T; Emberton M; Guillaumier S; Hindley RG; Hosking-Jervis F; Leemann L; Lewi H; McCartan N; Moore CM; Nigam R; Odgen C; Persad R; Thalmann GN; Virdi J; Winkler M; Ahmed HU
J Urol; 2020 Apr; 203(4):734-742. PubMed ID: 31928408
[TBL] [Abstract][Full Text] [Related]
11. Predictors of biochemical failure in patients undergoing prostate whole-gland salvage cryotherapy: a novel risk stratification model.
Spiess PE; Levy DA; Mouraviev V; Pisters LL; Jones JS
BJU Int; 2013 Aug; 112(4):E256-61. PubMed ID: 23469778
[TBL] [Abstract][Full Text] [Related]
12. Early prostate-specific antigen relapse after radical retropubic prostatectomy: prediction on the basis of preoperative and postoperative tumor characteristics.
Graefen M; Noldus J; Pichlmeier U; Haese A; Hammerer P; Fernandez S; Conrad S; Henke R; Huland E; Huland H
Eur Urol; 1999; 36(1):21-30. PubMed ID: 10364651
[TBL] [Abstract][Full Text] [Related]
13. Correlation of pretreatment clinical parameters and PSA nadir after high-intensity focused ultrasound (HIFU) for localised prostate cancer.
Ganzer R; Bründl J; Koch D; Wieland WF; Burger M; Blana A
World J Urol; 2015 Jan; 33(1):99-104. PubMed ID: 24696277
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors after salvage radiotherapy alone in patients with biochemical recurrence after radical prostatectomy.
Song W; Jeon HG; Sung HH; Jeong BC; Seo SI; Jeon SS; Choi HY; Lee HM
Int J Urol; 2016 Jan; 23(1):56-61. PubMed ID: 26502086
[TBL] [Abstract][Full Text] [Related]
15. Pathological, Oncologic and Functional Outcomes of a Prospective Registry of Salvage High Intensity Focused Ultrasound Ablation for Radiorecurrent Prostate Cancer.
Siddiqui KM; Billia M; Arifin A; Li F; Violette P; Chin JL
J Urol; 2017 Jan; 197(1):97-102. PubMed ID: 27422297
[TBL] [Abstract][Full Text] [Related]
16. Urethra-sparing high-intensity focused ultrasound for localized prostate cancer: Functional and oncological outcomes.
Shoji S; Nakano M; Fujikawa H; Endo K; Hashimoto A; Tomonaga T; Terachi T; Uchida T
Int J Urol; 2015 Nov; 22(11):1043-9. PubMed ID: 26251127
[TBL] [Abstract][Full Text] [Related]
17. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
18. Seven years of experience with high-intensity focused ultrasound for prostate cancer: advantages and limitations.
Sung HH; Jeong BC; Seo SI; Jeon SS; Choi HY; Lee HM
Prostate; 2012 Sep; 72(13):1399-406. PubMed ID: 22253052
[TBL] [Abstract][Full Text] [Related]
19. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database.
Mithal P; Howard LE; Aronson WJ; Kane CJ; Cooperberg MR; Terris MK; Amling CL; Freedland SJ
Int J Urol; 2015 Apr; 22(4):362-6. PubMed ID: 25728968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
